Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous L-Citrulline (Turnobi) for Acute Hypoxemic Respiratory Failure in COVID-19
NCT04570384Phase 2Completed
- Sponsor
- Asklepion Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute hypoxemic respiratory failure (AHRF) and coronavirus disease 2019 (COVID-19) comparing L-Citrulline Arm with Placebo Arm (2 arms). Primary endpoints: Time to Non-invasive/Invasive Mechanical Ventilation at Day 60, Time to Non-invasive Mechanical Ventilation at Day 60 and 4 more. Started Oct 2020; status: completed.
02
Drugs
citrulline
03
Conditions
acute hypoxemic respiratory failure (AHRF)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04570384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570384.